title: Letter by Liu et al regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".
authors.affiliation: Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
authors.forename: Mao
authors.initials: M
authors.lastname: Chen
authors.forename: De-Jia
authors.initials: DJ
authors.lastname: Huang
mesh_terms: D017130:Angioplasty; D003324:Coronary Artery Disease / Q000453:epidemiology* / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000453:epidemiology*; D005260:Female; D006801:Humans; D008297:Male; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D045162:Thiazolidinediones